Salesforce (CRM) just delivered one of enterprise software's biggest earnings beats of the quarter. The score was sitting at 1.5 stars going in. Here's what actually shifted post-results, and why the headline beat doesn't tell the whole story.
What changed in CRM's Stoxcraft scores this week
The scores that react fastest to price action and market sentiment moved first. The scores tied to multi-year fundamentals didn't move at all, and that distinction is the entire article.
How the trend and entry signal shifted after earnings
Before results dropped, the short-term technical picture for CRM was as bearish as it gets. Every indicator was pointing down. RSI had been sitting in deeply oversold territory. The MACD was negative. The stock was trading nearly 35% below its 52-week high.
Post-earnings, that picture improved. The stock held its level. The MACD turned positive for the first time in months. RSI normalized out of oversold territory toward the mid-40s range, which is historically a more neutral entry window. The trend signal moved two levels, from the most bearish reading to a slight downtrend. The entry signal lifted from Sell to Hold. That's a meaningful shift in the short-term setup.
What the Health and Performance scores show
Neither moved. That's not a bug. The Health Score refreshes on a quarterly data cycle, so it won't reflect Q1 FY2027 numbers until the underlying financial data propagates through. It currently sits at 7.0/10, placing CRM in the top tier for enterprise software fundamentals. That was true before earnings, and it remains true now.
The Performance Score is the harder problem. At 0.4/10, it reflects CRM's position near the very bottom of the Stoxcraft universe for price return. A 33% year-to-date decline against an S&P 500 up roughly 10% across every measured time window produces a score that one quarter cannot fix. The Performance Score is built on sustained relative returns. One beat doesn't erase the gap.
The news behind CRM's score improvement
Salesforce reported non-GAAP EPS of $3.88 against a consensus estimate of $3.12, a 24% earnings surprise. Revenue of $11.13 billion exceeded the $11.06 billion forecast.
The company also reported Agentforce now has more than $1 billion in annual recurring revenue, combined AI and data ARR of $3.4 billion, and 3.8 billion Agentic Work Units delivered for customers. That's the commercial evidence management has been pointing to all year. Agentforce isn't just a product announcement. It's showing up in the numbers.
The structural fear going into earnings was specific. Salesforce built its revenue model on software seats. One license per human user. If AI agents replace those users, the seat model shrinks. The Q1 results didn't eliminate that fear, but they gave it a harder number to lean on.
Despite the strong beat, the stock declined after hours. Salesforce raised FY2027 guidance to $45.9 to $46.2 billion, but the top end came in slightly below the most optimistic Street models. Q2 guidance implies roughly 10% constant-currency growth, a step down from Q1's 12%.
That guidance gap is why the stock barely moved on a 24% EPS beat. The market wasn't grading the quarter. It was grading the trajectory.
Is CRM's score rise structural or temporary
The honest answer is: partly both, and they apply to different scores.
What the trend improvement tells investors
The shift from Crashing to Dipping is a real change, but it's fragile. It reflects momentum stabilization, not momentum reversal. RSI in the mid-40s and a positive MACD after months of bearish alignment is an improvement. It doesn't mean the downtrend is over. It means the sharpest selling pressure has eased. If Q2 guidance disappoints in the next cycle, these indicators reverse quickly.
The entry signal moving from Sell to Hold also has a specific driver. Analyst coverage shifted post-earnings. Several analysts revised price targets upward after the beat while keeping cautious ratings. That moves the consensus average without creating a strong buy signal.
What would make the score recovery structural
The Performance Score requires sustained multi-year outperformance to recover from 0.4/10. That means CRM would need to consistently beat the S&P 500 across one-month, three-month, one-year, and longer windows. One quarter of price stability isn't enough.
The Health Score will refresh when Q1 FY2027 data is processed. Given the record margins reported, that update is likely to be positive. But a 7.0/10 Health Score was already pricing in a solid business. The upside from here on health is incremental.
Where CRM stands in the enterprise software sector
Enterprise software as a sector currently sits above the Stoxcraft universe average on health. CRM's Health Score of 7.0/10 is competitive within that group. What separates it from the sector's top names is the Performance Score. Most software companies in the top quartile are posting positive returns this year. CRM's 33% decline is an outlier in the wrong direction.
The sector's volatility profile is elevated broadly in 2026, driven by AI disruption fears. But CRM's Risk Score is higher than most of its software peers, reflecting a larger drawdown and a beta that amplifies market swings. A reading of 7.8/10 on risk means elevated volatility relative to roughly 80% of all stocks in the Stoxcraft database. That keeps the overall rating compressed regardless of how good the health numbers look.
Whether Salesforce's score recovery can hold through Q2
One good quarter from a fundamentally strong business. That's the most accurate description of where CRM sits right now.
The Health Score has always told a different story than the stock price. A 7.0/10 in enterprise software reflects strong free cash flow, solid operating margins, and a business that generates real cash. Salesforce generated $15 billion in operating cash flow in fiscal year 2026. That doesn't collapse in one bad year.
What the earnings report didn't fix is the narrative. The market wants proof that Agentforce revenue can accelerate fast enough to offset any seat-model erosion. Guidance came in slightly soft on Q2. Revenue acceleration is expected in the second half of FY2027, but it's still a forward promise.
Three things to watch that will determine whether this score rise holds:
- Agentforce ARR trajectory in Q2. The $1 billion ARR milestone matters less than the sequential growth rate.
- Q2 gross margin. Record non-GAAP margins of 34.8% in Q1 need to hold as Agentforce scales.
- Tableau and Commerce Cloud stabilization. Bookings and renewals are softening in two of Salesforce's core legacy segments. If those don't stabilize, the next Health Score update will reflect it.
The score is higher than it was a week ago. The structural work is still ahead.
